Clinical trial · Observational
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
Evaluation of Improvement of Quality of Life in Multiple Myeloma Patients Treated With Velcade (Bortezomib) IV: Prospective, Multicenter, Observational Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study will observe the degree of the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions). Both tools are validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma by analyzing factors that affect the quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bortezomib | Drug | Bortezomib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- 001
- interventionNames
- Drug: bortezomib
Primary outcomes (1)
- measure
- The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib
- timeFrame
- Before the first, after the fourth and at the last IV cycle of bortezomib
Secondary outcomes (4)
- measure
- Relationship between the primary outcome and the complete remission (CR) rate
- timeFrame
- Before the first, after the fourth and at the last IV cycle of bortezomib
- measure
- Relationship between the primary outcome and the overall response rate
- timeFrame
- Before the first, after the fourth and at the last IV cycle of bortezomib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are newly prescribed bortezomib injection as a secondary agent for the treatment of multiple myeloma * Patients who can understand and fill out quality of life questionnaires, and who agree to provide information will be included Exclusion Criteria: * Patients who are hypersensitive to the bortezomib or any component of bortezomib or with a history of the hypersensitivity * Patients with severe hepatic impairment * Pregnant women
References
Publications (0)
Data not yet available